Delivery Order SPE2DB20D2014-SPE2DB24FB15D
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,934.04 fixed-price delivery order is for the supply of Mesalamine 800 mg delayed-release tablets. The contract has a completion date of January 31, 2023 and is not designated with a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,170.87, is for the delivery of 4,563,198,346 units of Mesalamine 800 mg delayed-release tablets. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,141.61, is for the delivery of Mesalamine 800 mg delayed-release tablets. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of Mesalamine 800 mg delayed-release tablets. The $13,126.28 firm fixed price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency. The contract has a period of performance through September 16, 2024 and does not have a set-aside designation. This award is likely part of a larger Indefinite Delivery Contract (IDC) vehicle the...
- This federal contract award is for the delivery of Mesalamine 800 mg delayed-release tablets to the Defense Logistics Agency (DLA), a defense agency. The $2,026.42 firm fixed-price delivery order contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of April 29, 2024. The contract award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora,...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,258.34, is for the delivery of Mesalamine delayed-release tablets to support federal healthcare programs. The award is a delivery order under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
- This federal contract award, valued at $7,326.71, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Mesalamine delayed-release tablets, a medication used to treat certain gastrointestinal conditions. The contract has an ultimate completion date of March 20, 2025 and is a firm fixed-price delivery order. This award is not associated with any set-aside...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of mesalamine delayed-release tablets. The $10,894.56 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $8,569.90, is for the delivery of 4,565,597,427 tablets of Mesalamine delayed-release 1.2 gram tablets. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of August 28, 2024. Amerisourcebergen has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,027.36, is for the delivery of 120 tablets of 1.2 gram Mesalamine delayed-release (DR) tablets. The contract is a firm fixed-price delivery order with an ultimate completion date of March 26, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB24FB15DDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,797.58 firm fixed-price delivery order is for Mesalamine 800 mg delayed-release tablets and has a completion date of February 23, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating it was awarded through full and open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.8k | 2/22/24 |